The Fort Worth Press - New 'vaccine-like' HIV drug could cost just $40: researchers

USD -
AED 3.67296
AFN 68.986845
ALL 88.969965
AMD 387.270403
ANG 1.802796
AOA 927.769041
ARS 961.531104
AUD 1.470588
AWG 1.8
AZN 1.70397
BAM 1.753208
BBD 2.019712
BDT 119.536912
BGN 1.752304
BHD 0.376921
BIF 2899.760213
BMD 1
BND 1.29254
BOB 6.912131
BRL 5.514604
BSD 1.000309
BTN 83.60415
BWP 13.223133
BYN 3.273617
BYR 19600
BZD 2.01627
CAD 1.35825
CDF 2871.000362
CHF 0.850342
CLF 0.033728
CLP 930.650396
CNY 7.051904
CNH 7.043005
COP 4151.84
CRC 519.014858
CUC 1
CUP 26.5
CVE 98.841848
CZK 22.451204
DJF 177.720393
DKK 6.681904
DOP 60.041863
DZD 132.138863
EGP 48.452557
ERN 15
ETB 116.075477
EUR 0.894904
FJD 2.200804
FKP 0.761559
GBP 0.75092
GEL 2.730391
GGP 0.761559
GHS 15.725523
GIP 0.761559
GMD 68.503851
GNF 8642.218776
GTQ 7.732543
GYD 209.255317
HKD 7.79145
HNL 24.813658
HRK 6.799011
HTG 131.985747
HUF 352.180388
IDR 15160.8
ILS 3.781915
IMP 0.761559
INR 83.48045
IQD 1310.379139
IRR 42092.503816
ISK 136.260386
JEP 0.761559
JMD 157.159441
JOD 0.708504
JPY 143.81504
KES 129.040385
KGS 84.238504
KHR 4062.551824
KMF 441.350384
KPW 899.999433
KRW 1332.490383
KWD 0.30507
KYD 0.833584
KZT 479.582278
LAK 22088.160814
LBP 89576.048226
LKR 305.193379
LRD 200.058266
LSL 17.560833
LTL 2.95274
LVL 0.60489
LYD 4.750272
MAD 9.699735
MDL 17.455145
MGA 4524.124331
MKD 55.221212
MMK 3247.960992
MNT 3397.999955
MOP 8.029402
MRU 39.752767
MUR 45.880378
MVR 15.360378
MWK 1734.35224
MXN 19.414904
MYR 4.205039
MZN 63.850377
NAD 17.560676
NGN 1639.450377
NIO 36.81526
NOK 10.484204
NPR 133.76929
NZD 1.60295
OMR 0.384512
PAB 1.000291
PEN 3.749294
PGK 3.91568
PHP 55.653038
PKR 277.935915
PLN 3.82535
PYG 7804.187153
QAR 3.646884
RON 4.449904
RSD 104.761777
RUB 92.240594
RWF 1348.488855
SAR 3.752553
SBD 8.306937
SCR 13.062038
SDG 601.503676
SEK 10.171204
SGD 1.291204
SHP 0.761559
SLE 22.847303
SLL 20969.494858
SOS 571.648835
SRD 30.205038
STD 20697.981008
SVC 8.752476
SYP 2512.529936
SZL 17.567198
THB 32.903649
TJS 10.633082
TMT 3.5
TND 3.030958
TOP 2.342104
TRY 34.122804
TTD 6.803666
TWD 31.981038
TZS 2726.202038
UAH 41.346732
UGX 3705.911619
UYU 41.33313
UZS 12729.090005
VEF 3622552.534434
VES 36.777762
VND 24605
VUV 118.722009
WST 2.797463
XAF 587.999014
XAG 0.03211
XAU 0.000381
XCD 2.70255
XDR 0.741335
XOF 588.001649
XPF 106.906428
YER 250.325037
ZAR 17.43056
ZMK 9001.203587
ZMW 26.482307
ZWL 321.999592
  • RBGPF

    58.8300

    58.83

    +100%

  • GSK

    -0.8200

    40.8

    -2.01%

  • BCC

    -7.1900

    137.5

    -5.23%

  • NGG

    0.7200

    69.55

    +1.04%

  • SCS

    -0.3900

    12.92

    -3.02%

  • CMSC

    0.0300

    25.15

    +0.12%

  • BP

    -0.1200

    32.64

    -0.37%

  • RELX

    -0.1400

    47.99

    -0.29%

  • BTI

    -0.1300

    37.44

    -0.35%

  • RYCEF

    0.0200

    6.97

    +0.29%

  • JRI

    -0.0800

    13.32

    -0.6%

  • RIO

    -1.6100

    63.57

    -2.53%

  • CMSD

    0.0100

    25.02

    +0.04%

  • AZN

    -0.5200

    78.38

    -0.66%

  • VOD

    -0.0500

    10.01

    -0.5%

  • BCE

    -0.1500

    35.04

    -0.43%

New 'vaccine-like' HIV drug could cost just $40: researchers
New 'vaccine-like' HIV drug could cost just $40: researchers / Photo: © GETTY IMAGES NORTH AMERICA/AFP/File

New 'vaccine-like' HIV drug could cost just $40: researchers

A new "vaccine-like" HIV drug that currently costs over $40,000 per person a year could be made for as little as $40, researchers estimated on Tuesday.

Text size:

The antiretroviral drug Lenacapavir, developed by US pharmaceutical giant Gilead, has been hailed as a potential game-changer in the fight against HIV.

Early trials have found the treatment is 100 percent effective in preventing HIV infection. And it only needs to be injected twice a year, making the drug far easier to administer than current regimens requiring daily pills.

"It's like having a vaccine basically," Andrew Hill, a researcher at the UK's Liverpool University, told AFP.

The treatment currently costs patients over $40,000 a year in a range of countries including the United States, France, Norway and Australia.

New research, which Hill presented at the International AIDS Conference in Munich on Tuesday, looked into how much the cost of making the drug could come down if Gilead allowed for cheaper generic versions to be manufactured.

A year's worth of the drug could be made for as little as $40 -- 1,000 times less than the current price -- according to the research, which has not been peer reviewed.

This price was based on production volumes equal to treating 10 million people.

If the drug was given to people at high risk of contracting HIV -- such as gay or bisexual men, sex workers, prisoners or notably young women in Africa -- it could "basically shut down HIV transmission," Hill emphasised.

"We could actually control the epidemic."

There were 1.3 million new HIV infections last year, while 39 million people are living with the virus, according to the World Health Organization.

- 'Opportunity to save the world' -

To estimate the cost, the researchers studied shipments of raw materials of the drug, and spoke to large generic manufacturers in China and India that already make its "building blocks," Hill said.

The international team of researchers has been proven right about similar estimates in the past, he added.

A decade ago, the team said that the cost of making Gilead's hepatitis C drug -- then priced at $84,000 a patient -- could plummet to $100 if generics were allowed.

"Now it costs just under $40 to cure Hepatitis C," Hill said.

The new research was announced a day after UNAIDS chief Winnie Byanyima called on Gilead to "make history" by opening up Lenacapavir to the UN-backed Medicines Patent Pool, which would allow generics to be sold under licence in low- and middle-income nations.

"Gilead has an opportunity to save the world," she told AFP.

A Gilead spokesperson told AFP that the firm is still waiting on phase 3 clinical trial data on using Lenacapavir to prevent HIV, so "it is too early to state" what it could have in the future.

The firm has a strategy to "supply high-quality, low-cost versions of Lenacapavir" in countries "where the need is greatest," the spokesperson said.

It is also "moving with urgency" to negotiate contracts for a voluntary licencing programme to "expedite access to those versions of lenacapavir in high-incidence, resource-limited countries," the spokesperson added.

A.Williams--TFWP